Related Experiment Videos
Carvedilol exerts more potent antiadrenergic effect than metoprolol in heart failure
Takashi Kohno1, Tsutomu Yoshikawa, Akihiro Yoshizawa
1Cardiology Division, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Insights
Carvedilol shows a stronger anti-adrenergic effect during exercise than metoprolol in heart failure patients. It also appears more effective for those with higher brain natriuretic peptide levels.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Uncertainty exists regarding metoprolol vs. carvedilol efficacy in congestive heart failure treatment.
- Beta-blockers are crucial in managing heart failure, but comparative effects require clarification.
Purpose of the Study:
- To compare the anti-adrenergic effects of metoprolol and carvedilol during exercise in heart failure patients.
- To evaluate the differential efficacy of these beta-blockers based on baseline brain natriuretic peptide (BNP) concentrations.
Main Methods:
- Fifty-three patients with mild to moderate heart failure (LVEF <40%) were randomized to open-label metoprolol or carvedilol.
- Adrenergic responsiveness during exercise was assessed by normalizing heart rate increase to plasma norepinephrine increase.
Main Results:
- Carvedilol significantly reduced the normalized heart rate increase during exercise, indicating a potent anti-adrenergic effect, unlike metoprolol.
- Cardiac function improved more favorably with carvedilol in patients with higher baseline plasma BNP levels.
Conclusions:
- Carvedilol demonstrates a more potent anti-adrenergic effect during stress compared to metoprolol in heart failure.
- Carvedilol's efficacy is superior in heart failure patients with elevated baseline BNP, suggesting tailored pharmacologic selection is important.
Background:
It is still uncertain whether or not there is a difference between metoprolol and carvedilol for the treatment of congestive heart failure. We attempted to determine the difference between the two beta-blockers in terms of their antiadrenergic effect during exercise in patients with heart failure and their efficacy based on the baseline plasma brain natriuretic peptide concentration.
Methods:
Fifty-three patients with mild to moderate heart failure with a radionuclide left ventricular ejection fraction <40% received open label metoprolol or carvedilol in a randomized fashion. The increase in the heart rate normalized to the increase in the plasma norepinephrine concentration during exercise, was calculated as an index of adrenergic responsiveness during exercise.
Results:
The increase in heart rate normalized by the increase in plasma norepinephrine concentration, decreased after the initiation of beta-blockers in the carvedilol group, but not in the metoprolol group. The change in cardiac function was more favorable for carvedilol than metoprolol in patients who exhibited a higher baseline brain natriuretic peptide concentration.
Conclusions:
Carvedilol exerts a more potent antiadrenergic effect than metoprolol during stress in patients with mild to moderate heart failure. Carvedilol appears to be more efficacious than metoprolol in patients who exhibit higher baseline brain natriuretic peptide concentrations. These differences should be kept in mind when selecting appropriate pharmacologic agents in the treatment of heart failure.
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:28Antihypertensive Drugs: Types of β-Blockers
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers